集采转向：药企报价策略分化，不再追求最低价入选

Core Viewpoint - The 11th batch of national drug centralized procurement has concluded, with 55 drugs selected, aiming to provide high-quality and affordable medications to patients by February 2026. The procurement process has shown a significant shift in pricing strategies among participating companies, reflecting their operational strategies and cost control capabilities [3][5][18]. Group 1: Procurement Results - A total of 445 companies participated in the bidding, with 272 companies and 453 products winning the proposed selection, marking a historical high in participation [5][14]. - The average price difference of selected products has significantly narrowed compared to previous batches, indicating a more competitive environment [5][18]. - The introduction of measures such as a "price anchor" to prevent extreme low pricing and the revival mechanism for non-selected bids has contributed to maintaining a relatively high selection rate [5][11]. Group 2: Pricing Strategies - Companies have begun to adopt differentiated pricing strategies, moving away from irrational low bidding to more rational pricing based on their own cost structures and market assessments [5][6]. - Smaller companies are focusing on cost-effective pricing, while larger firms are either significantly lowering prices or reallocating resources towards innovative products instead of competing in the generic drug market [6][12]. Group 3: Revival Mechanism - The revival mechanism allows companies that did not initially qualify to participate in the selection process if they agree to match the prices of selected competitors, encouraging more companies to supply at reasonable prices [11][12]. - This mechanism is seen as beneficial for larger market share companies, allowing them to participate without being forced into aggressive price competition [11][12]. Group 4: Clinical Implications - The ability to report quantities by brand rather than just by generic name has clinical significance, ensuring better stability and continuity in patient medication [14][17]. - The procurement process aims to meet clinical demand while also addressing the financial burden on patients, particularly for high-cost medications like Nintedanib, which is expected to see significant price reductions [17][18].